Company press releases
| Released | Company | Title | Industry | Topic |
|---|---|---|---|---|
| 14 Oct 2021 08:00 CEST |
VACCIBODY | Mandatory notification of intra group transfer of shares by primary insider’s related party | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 12 Oct 2021 18:18 CEST |
VACCIBODY | Mandatory notification of intra group transfer of shares by primary insider’s related party | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 04 Oct 2021 08:00 CEST |
VACCIBODY | Vaccibody to participate at Guggenheim Securities’ 2nd Annual Vaccine and Infectious Disease Days | 20103010 Biotechnology | Non-regulatory press releases |
| 30 Sep 2021 17:04 CEST |
VACCIBODY | Resolution to issue shares as a consequence of option exercise | 20103010 Biotechnology | Total number of voting rights and capital |
| 24 Sep 2021 16:40 CEST |
VACCIBODY | Mandatory notification of transfer of shares by primary insider to closely associated person | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 20 Sep 2021 16:54 CEST |
VACCIBODY | Vaccibody AS - Mandatory notification of intra group transfer of shares by primary insider’s related party | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 10 Sep 2021 17:06 CEST |
VACCIBODY | Vaccibody AS - Mandatory notification of intra group transfer of shares by primary insider’s related party | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 07 Sep 2021 18:04 CEST |
VACCIBODY | Share capital increase from exercise of warrants | 20103010 Biotechnology | Total number of voting rights and capital |
| 26 Aug 2021 06:30 CEST |
VACCIBODY | Vaccibody AS - Quarterly report Q2 2021 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 23 Aug 2021 08:30 CEST |
VACCIBODY | Vaccibody Q2 and half-year report 2021 webcast | 20103010 Biotechnology | Non-regulatory press releases |
| 12 Jul 2021 06:45 CEST |
VACCIBODY | Vaccibody enters into worldwide license agreement with Adaptive Biotechnologies for clinically validated SARS-CoV-2 T cell epitopes to combine in a second-generation T cell vaccine candidate to specifically address emerging SARS-CoV-2 variants of concern | 20103010 Biotechnology | Non-regulatory press releases |
| 29 Jun 2021 18:43 CEST |
VACCIBODY | Share capital increase from exercise of warrants | 20103010 Biotechnology | Total number of voting rights and capital |
| 29 Jun 2021 06:45 CEST |
VACCIBODY | Vaccibody to initiate a phase 1/2 trial to evaluate two second-generation SARS CoV-2 virus DNA vaccine candidates to address emerging variants of concern | 20103010 Biotechnology | Non-regulatory press releases |